Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients

NCT01565746 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostatic Neoplasms

Interventions

DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)
DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)
DRUG: Radium-223 dichloride (Xofigo, BAY88-8223)

Sponsor

Bayer